北京时间2023年03月13日21时48分，美国OTC市场Northwest Biotherapeutics Inc（NWBO.us）股票出现波动，股价急速下跌5.33%。截至发稿，该股报0.568美元/股，成交量4.8073万股，换手率0.00%，振幅5.00%。

最近的财报数据显示，该股实现营业收入1.68百万美元，净利润-1.05亿美元，每股收益-0.10美元，毛利135000.00美元，市盈率-5.66倍。

机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。

美国OTC市场Northwest Biotherapeutics Inc股票所在的生物技术行业中，整体涨幅为2.11%。其相关个股中，Provention Bio Inc、Calliditas Therapeutics Ab、Clearmind Medicine Inc涨幅较大，Tenax Therapeutics Inc、Clearmind Medicine Inc、Aridis Pharmaceutical Inc较为活跃，换手率分别为%、%、%，振幅较大的相关个股有Pasithea Therapeutics Corp C/Wts 12/08/2026 (To Pur Com)、Lipocine Inc、Eqrx Inc C/Wts 17/12/2026 (To Pur Com)，振幅分别为%、%、%。

美国OTC市场Northwest Biotherapeutics Inc公司简介：Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

（以上内容为自选股智能机器写手Money Call完成，仅作为用户看盘参考，不作为交易依据。）